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Background: Approximately half of stroke survivors experience fatigue. Fatigue may persist for many 142 
months and interferes with participation in everyday activities, and has a negative impact on social 143 
and family relationships, return to work, and quality of life. Fatigue is among the top 10 priorities for 144 
‘Life after Stroke’ research for stroke survivors, carers and clinicians. We previously developed and 145 
tested in a small uncontrolled pilot study a manualised, clinical psychologist-delivered, face-to-face 146 
intervention, informed by cognitive behavioural therapy (CBT). We then adapted it for delivery by 147 
trained therapists via telephone. We now aim to test the feasibility of this approach in a parallel 148 
group, randomised controlled feasibility trial (Post Stroke Intervention Trial In Fatigue, POSITIF). 149 
Methods/design: POSITIF aims to recruit 75 stroke survivors between 3 months and 2 years post-150 
stroke who would like treatment for their fatigue. Eligible consenting stroke survivors will be 151 
randomised to either a 7-session manualised telephone delivered intervention based on CBT 152 
principles plus information about fatigue, or information only. The aims of the intervention are to: (i) 153 
provide an explanation for post-stroke fatigue, in particular that it is potentially reversible (an 154 
educational approach), (ii) encourage participants to overcome the fear of taking physical activity, 155 
and challenge negative thinking (a cognitive approach) and (iii) promote a balance between daily 156 
activities, rest and sleep and then gradually increase levels of physical activity (a behavioural 157 
approach). Fatigue, mood, quality of life, return to work and putative mediators will be assessed at 158 
baseline (just before randomisation), at the end of treatment and six months after randomisation. 159 
POSITIF will determine the feasibility of recruitment, adherence to the intervention, and the 160 
resources required to deliver the intervention in a larger trial.  161 
Discussion: The POSITIF feasibility trial will recruit until 31 January 2020. Data will inform the utility 162 
and design of a future adequately powered randomised controlled trial. 163 
Trial registration: ClinicalTrials.gov, NCT03551327. Registered on 11 June 2018. 164 
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 167 
Background 168 
Approximately 130,000 people have a stroke each year in the UK [1, 2]. Of these, almost a half will 169 
experience post-stroke fatigue [3]. Fatigue can be defined as a subjective feeling of lack of energy, 170 
weariness and aversion to effort [4] and in many cases becomes a chronic symptom that has an 171 
adverse effect on a person’s ability to manage everyday activities, socialise and maintain intimate 172 
relationships and to return to paid employment [5, 6]. The self-reported quality of life of fatigued 173 
stroke survivors is often very low [7]. It is therefore not surprising that the need to find effective 174 
treatments for fatigue was amongst the top 10 priorities for ‘Life after Stroke’ research shared by 175 
stroke survivors, carers, clinicians and researchers [8]. 176 
 177 
The search for effective treatments for post-stroke fatigue has been challenging. There has been 178 
little success in identifying biological causes. For example, there is no clear association between 179 
fatigue and the severity of stroke or stroke lesion location [9]. Perhaps not surprisingly, biological 180 
treatments have so far been shown to be ineffective at alleviating fatigue in this population [10]. 181 
Therefore, in order to identify intervention targets in a broader context of stroke illness, we 182 
conducted a systematic review to explore the correlates of post-stroke fatigue [11]. Drawing on this 183 
evidence and our qualitative study of the experiences of individuals with post-stroke fatigue [12], we 184 
developed a stroke-specific model of fatigue, which proposed that depressive symptoms, anxiety, 185 
low self-efficacy, passive coping, reduced physical activity, sleep problems, and inadequate social 186 
support are all important factors in the development and/or maintenance of fatigue [13]. These 187 
associations are consistent with findings from a qualitative study in which patients with post-stroke 188 
fatigue reported that rehabilitation and good sleep improved fatigue symptoms [12]. Figure 1 189 




[INSERT FIGURE 1 HERE] 192 
 193 
The psychological, behavioural and environmental factors outlined above are consistent with 194 
cognitive behavioural models for functional neurological symptoms [e.g. 14] where these factors are 195 
interconnected and may cause or maintain fatigue symptoms, and our earlier work treating fatigue 196 
in the population [15,16] and cancer-related fatigue [17]. The premise of cognitive behavioural 197 
therapy (CBT) is that addressing unhelpful thoughts and behaviours can change how people feel 198 
physically and emotionally [14]. We hypothesised [13] that increasing physical activity would be a 199 
starting point to break this ‘vicious cycle’ of post-stroke fatigue, because increasing activity levels 200 
would challenge cognitive barriers to activity (e.g. “This discomfort when I move is a sign I should 201 
take it easy”). The experience of being more active would then improve patients’ self-efficacy in 202 
taking physical activity, and thus reduce fatigue and improve mood [18]. There is an association 203 
between post-stroke fatigue and inactivity [19] and, therefore, increasing activity levels after stroke 204 
is a key component of the intervention. 205 
 206 
To test these ideas, we created a brief manualised intervention with input from stroke survivors and 207 
stroke clinicians [20]. The intervention aimed firstly to provide individuals with an explanation of 208 
post-stroke fatigue based on the psychological factors identified following systematic review of the 209 
literature, and to explain that the impact of post-stroke fatigue is reversible. Secondly, it encouraged 210 
fatigued stroke survivors to overcome any fears they might have about taking physical activity, 211 
specifically to challenge negative thoughts about their fatigue (e.g. “There’s nothing I can do about 212 
this”), that is to say a cognitive approach. Thirdly, the intervention promoted a balance between 213 
daily activities, rest and sleep, aiming for individuals to increase in increments their level of physical 214 
activity using diary monitoring and activity scheduling, in other words, a behavioural approach [15]. 215 
At the development phase, the intervention was delivered in an uncontrolled pilot study to 12 216 
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participants with post-stroke fatigue by a clinical psychologist with a special interest in stroke, to 217 
determine preliminary acceptability and feasibility [20]. The intervention comprised a participant 218 
handbook that included forms for diary keeping, six face-to-face treatment sessions, and one follow-219 
up telephone-delivered review (‘booster’) session. Fatigue levels were lower at the end of the study 220 
than at baseline for the eight individuals who completed treatment, and all participants reported 221 
favourable opinions of the intervention [20]. 222 
 223 
Following publication of the findings from this small observational trial, the trial intervention 224 
handbooks were edited taking into account participant feedback. We added new information about 225 
stroke survivors’ experiences of fatigue following a workshop about post-stroke fatigue at the Stroke 226 
Association UK Stroke Assembly (a conference for stroke survivors) in July 2017. At this point, a 227 
decision was made that for the next stage of intervention development, the Post Stroke Intervention 228 
Trial In Fatigue (POSITIF) would be delivered by trained nurses or other allied health care 229 
professionals (AHPs) or psychology graduates with training in CBT rather than clinical psychologists; 230 
the latter are too few in number to deliver this intervention across a national health care system, but 231 
nurses and other AHPs are core members of most stroke care teams, and are potentially a more cost 232 
effective option.  233 
 234 
For pragmatic reasons, it was decided that the intervention would have a better chance of being 235 
accepted by clinical services if it could be offered to participants via telephone rather than face-to-236 
face. This is because stroke services would struggle to offer treatments, even ones that are clinically 237 
effective, if the resources required to deliver them were too great. We were also mindful of the fact 238 
that many stroke survivors, particularly those with fatigue, struggle to get to hospitals and clinics so 239 




A telephone approach is justified as there is evidence from the literature that telephone-based 242 
delivery of CBT is feasible and effective. For example, a meta-analysis of 8 studies recruiting 658 243 
participants with a range of physical problems including stroke revealed that telephone counselling, 244 
delivered by therapists or psychologists, resulted in significant improvements in coping skills and 245 
strategies, community integration and reduction in depression [21]. In participants with traumatic 246 
brain injury, seven scheduled telephone sessions over nine months designed to elicit current 247 
concerns, provide information, and facilitate problem solving in domains relevant to traumatic brain 248 
injury recovery were associated with lower depression scores compared with usual care [22]. Our 249 
previous work in chronic fatigue syndrome had suggested that telephone treatment was acceptable 250 
to patients in a small randomised controlled trial [23].  251 
 252 
The aim of this trial is to assess the feasibility of our trial methods. 253 
 254 
Methods 255 
Study registration 256 
The study design was approved by the East of Scotland Research Ethics Committee (30 January 257 
2018).  The trial was registered with the U.S. National Institutes of Health on ClinicalTrials.gov (11 258 
June 2018) with trial identification NCT03551327. Recruitment commenced in January 2019 and is 259 
currently ongoing. 260 
 261 
Trial design 262 
The study is a UK-based, multi-site, randomised controlled feasibility trial including participants with 263 
post-stroke fatigue with broad entry criteria and follow-up to ascertain outcomes at six months after 264 
randomisation. The primary aim of the POSITIF feasibility trial is to ascertain recruitment rates, 265 
participant adherence to the intervention, and completeness of data capture during intervention 266 
delivery and at follow-up. At the time of submission to ClinicalTrials.gov our intention was to move 267 
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seamlessly from a feasibility trial to an efficacy trial without stopping and analysing data. However, 268 
our application for further funding was not successful and so a decision was made to analyse and 269 
report data from the feasibility trial as described in this paper, in line with our pre-specified criteria 270 
for moving to the main phase of the trial.   271 
 272 
The expected flow of participants through the trial is shown in Fig. 2.  273 
 274 
[INSERT FIGURE 2 HERE] 275 
 276 
Sample size 277 
The recruitment period is 14 months and we aim to recruit at least 75 participants in total from 278 
three hospital sites and online self-identification. This number is consistent with recommended 279 
sample sizes for pilot randomised controlled trials (RCTs) [24], 60-100 participants generally being 280 
required to estimate event rates in a single group. We will monitor recruitment rates closely so that 281 
any issues or barriers to recruitment can be identified and resolved. 282 
 283 
Participants 284 
We aim to recruit participants who meet the eligibility criteria (see below). A three-pronged 285 
approach to recruitment, namely retrospective, prospective and self-identification will be used.  286 
 287 
For retrospective recruitment, each site will identify potentially eligible participants by screening 288 
stroke registers, audit databases, patient hospital discharge summaries and The Scottish Health 289 
Research Register (SHARE), and through nurses and support workers who see patients after 290 
discharge from hospital. In Scotland, nurses from the charity Chest Heart and Stroke Scotland (CHSS) 291 
visit most patients after discharge from hospital. The retrospective approach will be used until the 292 
‘pool’ of potential participants who have had a stroke within the previous two years has been 293 
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reached. Individuals identified as being potentially eligible will be contacted by letter or in person by 294 
a member of the clinical team (including, but not limited to, the lead clinician for the service, the 295 
individual’s hospital consultant or charge nurse) with an invitation to participate in the screening 296 
process and the trial if eligible; a participant information sheet and a consent form will be provided. 297 
If no response is received from the letter of invitation within two weeks, the local team will 298 
telephone the individual to ensure that the information was received and answer any questions they 299 
might have. Screening questionnaires and consent forms will be completed by participants at home 300 
and returned to the research team by post or by email. 301 
 302 
For prospective recruitment, participants will be identified shortly after their hospital admission for 303 
stroke, at outpatient stroke clinics, or soon after discharge from hospital by the stroke nurses who 304 
visit patients in the community (generally three weeks following discharge). The initial approach to 305 
the patient will be in person by a member of the clinical team. Consent will be obtained for 306 
subsequent screening three months after stroke onset, and for participation in the trial if eligible. If a 307 
patient is ‘missed’ whilst in hospital (e.g. due to a very short hospital stay), then they will be 308 
contacted as for the retrospectively recruited participants. If a patient consents but does not return 309 
the screening questionnaires, a telephone call will be made to find out if they wish to take part. 310 
 311 
Finally, individuals will be able to identify themselves as potential feasibility trial participants from 312 
the web links of the UK’s two main stroke charities, CHSS (Selfhelp4stroke, a self-management 313 
resource for anyone who has had a stroke, and Stroke4 carers, an information and signposting portal 314 
for the carers and families of stroke survivors) and The Stroke Association (My Stroke Guide, a 315 
website providing resources and information to people affected by stroke). Those who are recruited 316 
in this way will participate in screening as described above. 317 
 318 
Inclusion criteria 319 
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 Age ≥ 18 years 320 
 Stroke (ischaemic or haemorrhagic, first or recurrent, and including subarachnoid haemorrhage) 321 
between 3 months and 2 years previously, based on clinical diagnosis and compatible imaging 322 
 Capacity to provide informed consent 323 
 Not living in a nursing home at time of consent 324 
 Medically stable 325 
 Answers ‘Yes’ to both of the following questions from the Greater Manchester Stroke 326 
Assessment Tool (GM-SAT) [25] about fatigue: ‘Do you feel tired all the time or get tired very 327 
quickly since your stroke’? and ‘Would you like additional help and support for this’? 328 
 329 
Exclusion criteria 330 
 Unlikely to be available for follow-up for the next six months e.g. no fixed home address 331 
 Life-threatening illness (e.g. advanced cancer or advanced heart failure) that would make 332 
survival for six months unlikely 333 
 Aphasia or cognitive impairment severe enough to prevent participation in the intervention. To 334 
assess this, participants will self-report their language and cognition from the relevant domains 335 
of the Short Stroke Impact Scale (SF-SIS) [26] (‘In the past week, how difficult was it for you to 336 
think quickly’? and ‘In the past week, how difficult was it to understand what was being said to 337 
you in a conversation’?). Those who respond ‘very difficult’ or ‘could not do at all’ to either 338 
question, or those whose communication impairment means that they are unable to respond to 339 
such questions at all, will be excluded 340 
 Actively suicidal, requiring in-patient treatment for depression, or experiencing depression-341 
related cognitive impairment 342 
 High anxiety as part of a post-traumatic stress disorder (PTSD) syndrome or panic disorder 343 
 Previously enrolled in this trial 344 
 Enrolled in another trial of psychological therapy 345 
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 Enrolled in another trial of physical activity 346 
 Inability to understand spoken and/or written English  347 
 348 
If a participant scores ≥15 (the threshold for moderately severe depression) or scores 1, 2 or 3 the 349 
suicidal item on the Patient Health Questionnaire 9-item (PHQ-9) [27] they will be telephoned by a 350 
member of the research team to ascertain the individual’s level of risk. We will write to the 351 
participant and their General Practitioner (GP). The GP will be advised of the score and what this 352 
means, and that we suggest further investigation and treatment. The same procedure – writing to 353 
participant and GP – will take place if a participant scores ≥15 on the Generalised Anxiety Disorder 7-354 
item (GAD-7) [28] (the usual threshold for severe anxiety). We will not inform participants of their 355 
scores but we will inform them that screening has indicated possible problems with their mood or 356 
anxiety and that we strongly encourage them to discuss this with their GP. Individuals will be 357 
excluded only if they are actively suicidal, requiring in-patient treatment or have depression-related 358 
cognitive impairment or if the individual has a PTSD syndrome or panic disorder (see above). In such 359 
situations, specific intervention from psychiatry or psychology would be needed before joining the 360 
POSITIF trial. 361 
 362 
Co-enrolment 363 
Inclusion in another research study, including another randomised controlled trial, will not 364 
automatically exclude an individual from participating in POSITIF. As long as inclusion in the other 365 
study would not confound the results of POSITIF, co-enrolment will be permissible. 366 
 367 
However, if someone has already been enrolled into a trial of a psychological therapy, they cannot 368 
be enrolled into POSITIF. If a participant is enrolled into POSITIF and is still being follow-up, they may 369 
not subsequently be enrolled into a trial of psychological therapy. If an individual has been recruited 370 




When considering co-enrolment, we will be mindful of the potential burden upon participants, their 373 
families and research staff. 374 
 375 
Consent to participate 376 
Eligible participants will be given a Patient Information Sheet (PIS) that explains what is involved in 377 
the study and an Informed Consent Form (ICF). If the potential participant requires additional 378 
information, they can contact the POSITIF trial team in the Edinburgh Clinical Trials Unit (ECTU) or 379 
the local investigator. We have developed ‘easy access’ materials (PIS, ICF and participant handbook) 380 
to support the participation of people with communication difficulties with input from people with 381 
aphasia.  382 
 383 
Participants will receive the PIS/ICF differently depending on how they are identified:  384 
(a) Participants who are identified retrospectively will be sent an ‘invitation pack’ which includes an 385 
invitation cover letter, PIS, ICF and screening form 386 
(b) Participants who are identified prospectively will be either given the PIS only (if an in-patient and 387 
stroke occurred <3 months ago) and the ICF and screening form will be sent later, or they may 388 
be given/sent the invitation pack as described above if the stroke occurred ≥3 months ago   389 
(c) Participants who self-refer will either give consent on-line (via a secure webpage) or they will be 390 
sent an invitation pack as described above (the participant will be able to choose their 391 
preference). Participants who consent on-line will be sent a paper copy of the PIS for their 392 
records.   393 
 394 
Screening 395 
There will be 6 screening items:  396 
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a) Two simple screening questions for fatigue [25]: (Participants must answer ‘yes’ to both to be 397 
eligible): ‘Do you feel tired all the time or get tired very quickly since your stroke?; ‘Would you 398 
like additional help and support for this?’ 399 
b) Patient Health Questionnaire-9 (PHQ 9) [27]. The scores range from 0-27, with a higher score 400 
representing more severe depression  (0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately 401 
severe, 20-27 severe)   402 
c) Generalised anxiety disorder 7 (GAD-7) [28]. The score ranges from 0-21 with a higher score 403 
representing more severe anxiety (5, 10 and 15 are the thresholds for mild, moderate and 404 
severe anxiety respectively)  405 
d) ‘In the past week, how difficult was it for you to think quickly?’ (cognitive item from the Short 406 
Stroke Impact Scale, SF-SIS) [26] 407 
e) ‘In the past week, how difficult was it to understand what was being said to you in a 408 
conversation?’ (language item from the SF-SIS) [26] 409 
f) Besides your stroke, do you have any other serious or life-threatening illnesses? 410 
 411 
In addition to the screening items outlined above, information on stroke subtype will be obtained. 412 
We will assess this by asking the question “Was your stroke due to a bleed or a blood clot?” We did 413 
consider extracting information about stroke type from all participants’ medical case notes, but 414 
whilst this would be possible for participants identified by local recruitment sites, it would not be so 415 
easy to obtain this information for participants who self-identify for the study. In this feasibility trial 416 
we will assess the agreement between participant report and case note diagnosis for participants 417 
recruited locally. This will enable us to estimate the extent of incorrect classification. We will also 418 
collect self-reported Modified Rankin Score (simple question version) [29] to obtain information on 419 
level of dependence, and we will ask individuals to list their medications and then answer the 420 
following question “Do you suffer from any of the following illnesses: cancer, heart failure, 421 
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rheumatoid arthritis, Parkinson’s disease, multiple sclerosis?” because all of these illnesses can cause 422 
fatigue [15, 16]. 423 
 424 
Those eligible will be asked to complete baseline data, and will be randomised through the trial 425 
database. If the participant completes the screening questionnaires, and is found to be eligible for 426 
randomisation, they will be sent a baseline data collection form for completion (either by email or by 427 
post), and will then be randomised.  428 
 429 
We anticipate that some participants may change their mind after being found to be eligible to 430 
participate. If we do not receive the baseline data, the participant will be telephoned.  If the baseline 431 
data are not returned even after a telephone call, we will categorise the participant as having 432 
consented, been found to be eligible, but not randomised. 433 
 434 
Withdrawal of Study Participants 435 
Participants may consent, be eligible, and then change their minds at a later time. The participant’s 436 
doctor may advise them to stop participating in the intervention. We will record how often each of 437 
these scenarios occur. We will still follow-up the participant per protocol and collect six month 438 
follow-up data for the primary analyses. However, if a participant chooses to withdraw completely 439 
from the trial and not participate in follow-up, we will retain the data collected on that participant 440 
up to that point. 441 
 442 
If a participant loses capacity during the trial, no further follow-up will be obtained but we will retain 443 
data already collected.  444 
 445 
This intervention is low risk and we do not anticipate major problems. However, should a participant 446 
develop any contraindication to participation during the intervention, for example due to severe 447 
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deterioration in mental state, they will stop participating in the intervention but will continue to be 448 
followed up. If the contraindication resolves within four weeks, the participant will be allowed to 449 
restart the intervention and complete the six sessions and the booster phone call. 450 
 451 
Randomisation 452 
Each participant’s screening and baseline data will be entered into a computerised central 453 
randomisation service by means of a secure 24/7 web interface. After the computer program has 454 
checked data for completeness and consistency, it will allocate the participant a unique study 455 
identification number and assign them to either the intervention or the control arm of the study. 456 
The system applies a minimisation program to achieve balance for three factors, namely: (i) time 457 
since stroke (as fatigue tends to improve over time; <1 year versus ≥1 year) [3], (ii) sex (since fatigue 458 
tends to be more common in women) [30], and (iii) depression score at baseline (since those with 459 
more depressive symptoms may have more severe fatigue and so respond differently to the 460 
intervention) [11]. Minimisation on anxiety and fatigue will not be required because depression, 461 
anxiety and fatigue tend to be highly correlated [11]. 462 
 463 
The randomisation record will be stored within the trial database. Following randomisation to either 464 
the intervention or control arm, a letter will be sent to the participant’s GP to inform them of their 465 
patient’s enrolment in the trial with a copy of the signed participant consent form. The participant 466 
will be informed by telephone, email or post about the randomisation outcome. The intervention 467 




This is a pragmatic trial. As stroke psychologists are scarce in the United Kingdom National Health 472 
Service (NHS) [31], it was decided that nurses or AHPs would be trained to deliver the intervention. 473 
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The nurse/AHP therapists will receive standardised training from an experienced stroke clinical 474 
psychologist (DG) and fatigue expert and cognitive behavioural psychotherapist (TC) in how to 475 
deliver the intervention, and how to record the content of each session using a checklist. The one-476 
day training will comprise an overview of the literature on post-stroke fatigue as well as an 477 
introduction to the principles and practice of CBT, including role play and group discussion; reading 478 
materials for self-study will be also provided. 479 
 480 
The delivery of the intervention will be by telephone. Trial materials (including written information 481 
about fatigue, a participant handbook, participant diary, and follow-up questionnaires) have been 482 
made available on a trial website (www.ed.ac.uk/usher/edinburgh-clinical-trials/our-studies/all-483 
current-studies/positif/the-positif-trial).  484 
 485 
The intervention will be tailored towards the specific needs of participants, including their existing 486 
activity levels. For example, after the first session, the participant completes diaries to record activity 487 
and sleep. Then, based on those diaries, goals related to increasing activity and improving sleep are 488 
negotiated. The content of goals will be individualised and inevitably vary between participants. The 489 
participant handbook includes information sheets about how pain, medication and other medical 490 
conditions may be related to fatigue; participants will be sign-posted to the particular information 491 
relevant to them. 492 
 493 
The intervention comprises six sessions, each separated by two weeks. In the intervals between 494 
sessions, it is suggested that participants work on their chosen goals. At the final session, 495 
participants reflect on any gains made, how they were achieved, discuss potential set-backs  and 496 
make a plan to maintain and/or build on any behavioural changes they have made which may be 497 
influencing levels of fatigue. There is a review phone call two to four weeks after the sixth session, to 498 
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check on progress and to offer ongoing encouragement. An outline of the content and main focus of 499 
each session is provided in Table 1.  500 
 501 
All sessions will be audio recorded on encrypted voice dictation devices. Nurse/AHP therapists will 502 
receive fortnightly telephone supervision for the duration of the study (approximately 30-minutes 503 
per fortnight); the supervising psychologist (DG) will have the opportunity to listen to audio 504 
recordings before supervision sessions. Table 2 provides an overview of the rationale for the study, 505 
as well as study materials and procedures. 506 
 507 
[INSERT TABLE 1 HERE] 508 
 509 
[INSERT TABLE 2 HERE] 510 
 511 
Comparator 512 
Careful consideration was given to the nature of the control intervention. As there is no effective 513 
intervention for post-stroke fatigue that is routinely available in clinical practice, it is not possible to 514 
compare the active intervention in POSITIF with another active intervention. A ‘placebo’ control 515 
intervention such as relaxation was considered, but would have required considerable additional 516 
resources to administer, and may have been less acceptable to participants [32]. A wait list design 517 
was also considered in which no intervention would be provided during the experimental treatment 518 
period, with active treatment offered after the final follow up assessment, but this would also have 519 
needed additional resources. The participant handbook could have been provided to control 520 
participants at the end of the post-treatment assessment, but it was designed to be used with 521 
therapist input and could not be easily used by individuals without support and guidance. Finally, the 522 
control could have been ‘usual care’, but there were concerns that participants might decline the 523 
invitation to participate if there was a 50% probability of receiving nothing additional to routine 524 
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care. Therefore, it was decided to provide control participants with information about fatigue. 525 
Although information about post-stroke fatigue is easily available (e.g. from charity websites), our 526 
clinical experience is that patients are not usually signposted to it. A Cochrane review of information 527 
provision after stroke reported that information alone has a very small, probably not clinically 528 
significant effect on depression, though there are no data on the effect of information provision on 529 
fatigue [33]. A copy of the information leaflet, which is given immediately following randomisation, 530 
can be found at https://www.stroke.org.uk/sites/default/files/fatigue_after_stroke.pdf 531 
 532 
Table 3 provides a summary of the timing of treatment telephone calls and feasibility study 533 
assessments. 534 
 535 
[INSERT TABLE 3 HERE] 536 
 537 
Feasibility outcomes 538 
The following data will help to inform the design of a future main efficacy trial: 539 
 540 
Recruitment 541 
- The feasibility of individuals referring themselves for fatigue screening via links to patient websites 542 
including CHSS and The Stroke Association (number and rate) 543 
- The feasibility of identifying stroke survivors through local sites (number and rate) and the 544 
proportion who agree to fatigue screening 545 
- The number of stroke survivors who complete the screening questions, according to the method by 546 
which they were identified (by local sites or self-identification) 547 
- The proportion of individuals who undergo fatigue screening who are eligible to participate 548 
- The proportion of eligible patients who are randomised 549 
- The recruitment rates by different methods and by different sites  550 
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- The feasibility of identifying and training nurses and AHPs to deliver the intervention 551 
 552 
Adherence and retention 553 
- The adherence rate and reasons for non-adherence (number of sessions participants receive) 554 
- The fidelity of the intervention (i.e. therapist adherence to the manual) 555 
 556 
Data completion and data variability 557 
- The response and completion rates for postal and web-based questionnaires, and the proportion of 558 
participants requiring telephone calls to collect follow-up questionnaires 559 
- Variability in our fatigue outcome measure. 560 
 561 
Resources 562 
- The resources required to deliver the intervention 563 
 564 
A Data Monitoring Committee (DMC) will be established and a DMC charter will be written. In this 565 
feasibility trial, the Trial Management Group (the investigators) will provide oversight of the trial and 566 
will function as a Trial Steering Committee (TSC).  567 
  568 
Progression criteria 569 
We will proceed to an efficacy trial – which will require additional funding – if the following criteria 570 
are achieved in the feasibility trial: 571 
a) Recruit 75 participants in one year (from local sites and through self-referral e.g. links with 572 
relevant websites) 573 
b) Follow-up (primary outcome in at least 90% of participants) 574 
c) Adherence to therapy: at least four of the six sessions attended. 575 




If these criteria are not met, the TMG will explore the reasons for this and may still proceed with an 578 
efficacy trial if the reasons are addressable, for example sick leave amongst therapists delivering the 579 
intervention.    580 
 581 
Potential future outcome measures for an efficacy trial  582 
The following measures are not outcomes for this feasibility trial, but are potential measures for a 583 
future efficacy trial: 584 
- The Fatigue Assessment Scale (FAS). The FAS is a 10-item self-report scale that is valid and reliable 585 
in stroke [34]. The scale measures mental and physical fatigue. A difference of four points is 586 
considered to represent a clinically relevant change on this scale [35]. 587 
- Self-reported mood assessed using PHQ-9 [27] and the GAD-7 [28].  - We will enquire whether 588 
antidepressants or anxiolytics have been prescribed 589 
- Self-reported fearful beliefs in relation to exercise, to determine if these are a mediator in the 590 
effect of CBT on post-stroke fatigue, measured using the fear avoidance questions from the 591 
Cognitive and Behavioural Responses Questionnaire (CBRQ) [36]. The decision to include the CBRQ 592 
was made after the trial was registered with the National Institutes of Health, as an amendment to 593 
our protocol.   594 
- Stroke specific quality of life including participant-reported social participation, assessed using the 595 
Short Form of the Stroke Impact Scale (SF-SIS) [26]. 596 
- Quality of Life Adjusted Life Years (QALYs), assessed using the Euroqol 5D (5-level version) [37].  597 
The number of hours participants are working relative to before their stroke (participants asked to 598 
report average hours worked per week currently and immediately before stroke). 599 
- We will collect data on health costs (visits to the GP, number of admissions to hospital, days in a 600 
care home, number of visits from social carers, cost of the therapist delivery time, cost of the 601 
supervision time from psychology/psychiatry). In a future efficacy trial, this would enable us to 602 
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perform a health economic analysis which will tell us how much the intervention costs, whether 603 
there are savings in use of health/social care, and what QALYs are associated with the intervention. 604 
 605 
Statistical analysis 606 
We will report numbers and percentages for the tests of feasibility, without formal statistical testing.  607 
For the proposed outcome measures for a future efficacy trial, in this feasibility study we will 608 
present overall summaries across both treatment groups combined, such as mean and standard 609 
deviation, number and percentage, and proportion of missing data.  We will also test for differences 610 
between the randomised groups, but because this is a feasibility trial with a relatively small number 611 
of participants, we will refrain from drawing strong conclusions. A full statistical analysis plan will be 612 
written prior to database lock.  613 
 614 
Discussion 615 
A high proportion of stroke survivors experience fatigue. Post-stroke fatigue is negatively associated 616 
with physical, psychological and social functioning – particularly for those unfortunate enough to 617 
experience fatigue long term – there is little existing evidence from RCTs of effective treatments. 618 
However, absence of evidence is not the same as evidence of absence; psychological/behavioural 619 
treatments for post-stroke fatigue have simply not yet been put to rigorous scientific test.  620 
 621 
To address this gap, the feasibility stage of POSITIF aims to test the feasibility of a nurse/AHP 622 
provided, telephone-delivered CBT-informed intervention for individuals who experience fatigue 623 
three months to two years following stroke. We have preliminary data from a previous pilot study 624 
that indicates that the content and style of the intervention is acceptable. Small improvements have 625 
been made to the intervention protocol in the light of participant and therapist pilot study feedback. 626 
The main changes from the published uncontrolled pilot study have been to move from face-to-face 627 
to telephone delivery of the intervention and to have nurses and AHPs rather than clinical 628 
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psychologists deliver the intervention. These changes were made on clinical and pragmatic grounds. 629 
As far as mode of therapy delivery is concerned, there is published evidence for the efficacy of 630 
telephone delivered CBT interventions in clinical health populations, including participants with 631 
neurological injury [21, 22] and chronic fatigue syndrome [23], though we do acknowledge that 632 
delivery by telephone may be less acceptable to individuals with communication impairment. 633 
Delivery of the intervention by nurses and AHPs rather than clinical psychologists, is a more realistic 634 
proposition for health care systems such as the United Kingdom where clinical psychologists are in 635 
relatively short supply [31]. Therapists working in multidisciplinary IAPT (Improving Access to 636 
Psychological Therapies) teams could also deliver the intervention [38].  637 
 638 
The intervention may have several advantages over traditional face-to-face delivered CBT. Because 639 
the intervention is delivered by telephone, participants will be spared the expense of time and effort 640 
to travel to clinic appointments. It is especially important to consider the demands made on fatigued 641 
individuals in interventions of this type, because potential participants might be reluctant to commit 642 
scarce energy reserves to such interventions; as noted in a recent Cochrane review, fatigue trials 643 
often have high dropout rates [10]. Though the intervention is manualised, there is scope within it to 644 
negotiate goals with each participant. Indeed the emphasis is on empowering the individual at all 645 
stages of the intervention. It is hoped that this will enable individuals to make gains beyond the 646 
period of active treatment. The aim that participants become, in effect, their own therapists lies at 647 
the heart of CBT [14].  648 
 649 
Improvements in fatigue are not the only outcome of interest. As well as mood outcomes 650 
(depression and anxiety) we will record individuals’ social participation, how likely they are to return 651 
to paid work and their overall quality of life. These are important outcomes, because one would 652 
hope that if the intervention delivered in the POSITIF trial improves functioning via activity 653 
scheduling then participants’ level of fatigue will also improve. The importance of improvement in 654 
25 
 
key life roles is well recognised by so-called ‘third wave’ cognitive behavioural therapies [39, 40] 655 
which help people connect with personal values and do what matters to them. We also expect that 656 
treatment effects may be mediated by changes in fearful beliefs. Mechanisms of change will be 657 
assessed in a future trial.  658 
 659 
There are limitations and possible challenges. One is the possibility of loss to follow up, particularly 660 
the attrition bias that would occur if the most fatigued participants dropped out of the study. 661 
Although the intervention is relatively brief (10 weeks duration, excluding the booster session), as 662 
with all cognitive behavioural therapies, it demands active involvement on the part of the participant 663 
and home-based practice is expected following every treatment session. The key, we believe, is to 664 
make sure participants who sign up to the feasibility trial genuinely do want help to manage their 665 
fatigue and understand what is expected of them (without being off putting). Participant 666 
information sheets will make clear the active nature of the intervention. We will also perform a 667 
sensitivity analysis to compare the characteristics of individuals who complete the intervention with 668 
individuals who do not. We acknowledge that a limitation of this feasibility study is that intervention 669 
and control conditions are not matched for contact time, which may have a positive behavioural 670 
effect in itself. However, it would have been impractical within the constraints of funding to perform 671 
a three-arm feasibility trial. A larger efficacy trial might match participants in intervention and 672 
control arms for therapist contact time, perhaps comparing individuals receiving POSITIF with 673 
individuals receiving an equivalent amount of non-directive discussion about the general impact of 674 
stroke on everyday life, such as the unstructured social contact delivered as the control arm in a trial 675 
of communication therapy for aphasia and dysarthria following stroke [41]. 676 
 677 
Fatigue is a serious complication of stroke, blighting the lives of the large number of individuals who 678 
experience it. The findings will determine whether a randomised trial involving larger numbers of 679 





AHP: Allied Health Professional; CBRQ: Cognitive and Behavioural Responses Questionnaire; CBT: 683 
Cognitive Behavioural Therapy; CHSS: Chest Heart and Stroke Scotland; DMC: Data Monitoring 684 
Committee; ECTU: Edinburgh Clinical Trials Unit; EQ-5D-5L: EuroQoL 5-dimension 5-level; FAS: 685 
Fatigue Assessment Scale; GAD-7: Generalized Anxiety Disorder Assessment 7-item; GCP: Good 686 
Clinical Practice; GM-SAT: Greater Manchester Stroke Assessment Tool; GP: General Practitioner; 687 
HRQOL: Health Related Quality of Life; IAPT: Improving Access to Psychological Therapies; ICF: 688 
Informed Consent Form; NHS: National Health Service; PHQ-9: Patient Health Questionnaire 9-item; 689 
PIS: Patient Information Sheet; POSITIF: Post-stroke Intervention Trial in Fatigue; PTSD: Post 690 
Traumatic Stress Disorder; QALYs: Quality of Life Adjusted Years; RCT: Randomised Controlled Trial; 691 
SF-SIS: Short Form Stroke Impact Scale; SHARE: Scottish Health Research; TSC: Trial Steering 692 
Committee.  693 
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Figure 1.  A conceptual model of post-stroke a fatigue (unidirectional arrows indicating an assumed 846 
causal direction and bidirectional arrows indicating an unknown direction of association. Dotted 847 
arrows indicate potential interactions between factors). From Stroke re-published with permission 848 
  849 
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Figure 2. The POSITIF recruitment process 850 
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1 Engagement and preparation 
- Discuss the patient’s experience of post-stroke fatigue 
- Explain symptoms and potential mechanisms of post-stroke fatigue 
- Emphasise that maintaining factors are potentially reversible 
- Explain how to use a diary to monitor daily activities, rest and sleep 
2 Balancing daily activities, rest and sleep 
- Review diaries the patient has been keeping to determine current levels of activity, rest and sleep 
- Discuss strategies to improve sleep patterns 
- Set SMART goals to increase daily activities and improve sleep 
- Agree on an initial plan to balance activity levels, rest and sleep 
3 Increasing daily activities in graded increments 
- Review the patient’s diary and discuss progress with the initial plan 
- Discuss new goals to be achieved in the coming weeks (including decreasing the amount of rest) 
- Agree on a weekly plan to work towards new goals 
4 Improving emotions and thoughts 
- Discuss the ‘3-area model’ to explain the links between thoughts, emotions and behaviour 
- Discuss the unhelpful thoughts and emotions that might occur in response to fatigue 
- Introduce thought challenging sheets 
5 Dealing with difficulties in making progress 
- Identify common ‘blocks’ and setbacks in making progress 
- Discuss any problems the patient has experienced and agree with the patient solutions (patient taking 
active role) 
6 Preparing for the future 
- Check patient’s understanding of the intervention and discuss their progress 
- Encourage the patient to suggest new future targets and a plan for working towards them 




Review of overall progress 
- Evaluate the patient’s progress since session 6 
- Help the patient solve any outstanding problems 
- Review the patient’s understanding of treatment rationale and skills 
- Discuss further targets and plans 
 854 
 T  855 
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  Table 2. Overview of intervention rationale, materials and procedures 856 
Brief name of intervention  Post Stroke Intervention Trial In Fatigue (The POSITIF Trial)  
WHY (rationale for 
treatment) 
Post-stroke fatigue is common, experienced by approximately half of all stroke survivors. It has a 
negative impact on a range of important life domains. A systematic review of the literature found that 
psychological factors, namely depression, anxiety, low self-efficacy, passive coping, reduced physical 
activity, sleep problems and low levels of social support are implicated in the development or 
maintenance of fatigue following stroke. This evidence suggests that cognitive behavioural treatment 
methods, which target individuals’ thoughts, behaviours and feelings, and have been used to treat 
fatigue in other health conditions, could be effective in the treatment of post-stroke fatigue.   
WHAT (materials)  POSITIF is a manualised cognitive behaviourally informed treatment that targets the factors that have 
been associated with post-stroke fatigue in the literature. Individuals will receive a participant manual 
that includes written information about post-stroke fatigue, as well as activity and sleep diaries and 
worksheets for goal setting and thought challenging. Before POSITIF, the materials were provided to 12 
stroke survivors in a small uncontrolled pilot study and edited to take account of participant and 
clinician feedback (see Table 1).  
WHAT (procedures)  Information will be provided to participants about post-stroke fatigue and individuals will be given an 
opportunity to discuss their ‘model’ of fatigue, i.e. why they believe they experience it. Any 
misconceptions about fatigue will be corrected. Activity diaries and sleep diaries will be completed by 
participants throughout the intervention and sent to the therapist (by post); these will form the basis 
for a tailored approach designed to promote a balance between daily activities, rest and sleep, the aims 
being to gradually increase levels of physical activity, and to avoid ‘boom and bust’ activity patterns. 
Therapists will identify participant beliefs about fatigue and help participants to challenge negative 
thinking, encouraging them overcome any fears about undertaking physical activity (see Table 1). The 
comparator group will receive written information about fatigue only,  
in the form of a leaflet (available at www.strokeassociation/dudfuhfud.com).   
WHO (profession, 
expertise, specific training, 
etc)  
The intervention is to be delivered by nurses or Allied Health Professionals (AHPs). These therapists will 
be individuals with clinical experience of stroke, but no prior training in Cognitive Behavioural Therapy 
(CBT). They will be representative of the nurses who work with stroke survivors in community stroke 
settings. Therapists will receive a one-day training that comprises an overview of the literature on post-
stroke fatigue, an introduction to the principles and practice of CBT, and information on how to deliver 
the intervention, including how to record the content of sessions. A stroke clinical psychologist and a 
cognitive behavioural psychotherapist will deliver the training. Brief role plays and group discussions 
will be included; reading materials, including journal articles will be provided to trial therapists for self-
study. Nurse/AHP therapists will receive fortnightly telephone supervision (30-minutes duration) from 
the stroke clinical psychologist who delivers the training.   
HOW (modes of delivery)  POSITIF sessions will be telephone delivered. Phone calls will be made at times convenient to 
participants. Therapists will try to call participants at least two or three times before a session is classed 
as ‘missed’, as would happen in clinical practice. Participants will be required to have their written 
manuals in front of them during the calls so that therapists can direct them to particular worksheets 
and other materials.  
WHERE (infrastructure and 
relevant features)  
Participants will receive the telephone sessions in their own homes. They will receive the participant 
manuals by post.  
WHEN and HOW MUCH 
(number of sessions, 
duration, intensity, dose)  
The intervention comprises six sessions, one every two weeks. Sessions will be up to 60minutes in 
duration. In the intervals between sessions, participants will work on their chosen goals. A review 
‘booster’ telephone session will take place two to four weeks after the sixth session.   
TAILORING 
(personalisation)  
Goals will be individualised for each patient to take account of their baseline level of activity and sleep 
patterns, their physical health, levels of fatigue and their interests and aspirations.  
MODIFICATIONS (from 
existing or initial protocol)  
Any modifications that are required in the course of the intervention will be recorded.  
HOW WELL (planned 
adherence)  





















  Table 3. Summary of study assessments and treatment telephone calls 873 
 874 
  *The booster treatment telephone call can take place at 13, 14 or 15 weeks post randomisation 875 
 876 
  CBRQ: Cognitive and Behavioural Responses Questionnaire; EQ-5D-5L: EuroQoL 5-dimension 5-level; FAS: Fatigue  877 
  Assessment Scale; GAD-7: Generalized Anxiety Disorder Assessment 7-item; PHQ-9: Patient Health Questionnaire 9-item; 878 
  SF-SIS: Short Form Stroke Impact Scale 879 
 880 
 881 
  STUDY PERIOD  
 Enrolment Allocation Post-allocation Close-out 
TIMEPOINT (time 
in weeks) 






ENROLMENT:            
Consent and 
screening 
X           
Randomisation X           
Allocation  X          
INTERVENTION:            
Telephone call 1   X         
Telephone call 2    X        
Telephone call 3     X       
Telephone call 4      X      
Telephone call 5       X     
Telephone call 6        X    
Booster 
telephone call 
        X   
ASSESSMENTS:            
Baseline 
assessments: 




- SF-SIS cognitive item 
- SF-SIS language item 
- Screening questions 
about serious illness 

















- Anxiolytics (Y/N) 
- Hours working 
- Health costs 
          X 
